WallStreetZenWallStreetZen

NASDAQ: ACHV
Achieve Life Sciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ACHV

Based on 3 analysts offering 12 month price targets for Achieve Life Sciences Inc.
Min Forecast
$11.00+140.7%
Avg Forecast
$16.33+257.4%
Max Forecast
$20.00+337.64%

Should I buy or sell ACHV stock?

Based on 3 analysts offering ratings for Achieve Life Sciences Inc.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ACHV stock forecasts and price targets.

ACHV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-17
lockedlocked$00.00+00.00%2024-04-01
lockedlocked$00.00+00.00%2024-03-05

1 of 1

Forecast return on equity

Is ACHV forecast to generate an efficient return?
Company
N/A
Industry
-59.45%
Market
20.1%

Forecast return on assets

Is ACHV forecast to generate an efficient return on assets?
Company
N/A
Industry
5.95%

ACHV revenue forecast

What is ACHV's revenue in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
$48.5M

ACHV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACHV$4.57$16.33+257.40%Strong Buy
MDWD$16.99$28.00+64.80%Buy
CRVO$25.25$65.00+157.43%Strong Buy
CAPR$5.05$24.00+375.25%Strong Buy
INMB$8.80N/AN/A
View Top Biotech Stocks

Achieve Life Sciences Stock Forecast FAQ

Is Achieve Life Sciences Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: ACHV) stock is to Strong Buy ACHV stock.

Out of 3 analysts, 2 (66.67%) are recommending ACHV as a Strong Buy, 1 (33.33%) are recommending ACHV as a Buy, 0 (0%) are recommending ACHV as a Hold, 0 (0%) are recommending ACHV as a Sell, and 0 (0%) are recommending ACHV as a Strong Sell.

If you're new to stock investing, here's how to buy Achieve Life Sciences stock.

What is ACHV's revenue growth forecast for 2025-2025?

(NASDAQ: ACHV) Achieve Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.39%.

Achieve Life Sciences's revenue in 2024 is $0.

In 2025, ACHV is forecast to generate $1,661,217,684 in revenue, with the lowest revenue forecast at $1,661,217,684 and the highest revenue forecast at $1,661,217,684.

What is ACHV's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: ACHV) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 5.95%.

What is ACHV's Price Target?

According to 3 Wall Street analysts that have issued a 1 year ACHV price target, the average ACHV price target is $16.33, with the highest ACHV stock price forecast at $20.00 and the lowest ACHV stock price forecast at $11.00.

On average, Wall Street analysts predict that Achieve Life Sciences's share price could reach $16.33 by Apr 17, 2025. The average Achieve Life Sciences stock price prediction forecasts a potential upside of 257.4% from the current ACHV share price of $4.57.

What is ACHV's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: ACHV) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.